• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cardiologist as a cardiometabolic specialist.作为心脏代谢专家的心脏病专家。
J Clin Hypertens (Greenwich). 2019 Sep;21(9):1432-1435. doi: 10.1111/jch.13636. Epub 2019 Jul 29.
2
Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice.为急性冠状动脉综合征患者开具降糖药物以降低心血管风险：心脏病专家的态度与实践调查
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):194-196. doi: 10.1093/ehjcvp/pvz058.
3
Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.索格列净作为胰岛素治疗辅助药物对 1 型糖尿病成人患者血压和动脉僵硬度的影响：inTandem1 和 inTandem2 的事后 pooled 分析。
Diab Vasc Dis Res. 2021 Jan-Feb;18(1):1479164121995928. doi: 10.1177/1479164121995928.
4
Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.恩格列净治疗3个月对2型糖尿病患者动态血压和动脉僵硬度的影响。
Ann Afr Med. 2021 Apr-Jun;20(2):154-155. doi: 10.4103/aam.aam_19_20.
5
Cardiometabolic University 2017: Meeting Review and Presentation Summaries.2017年心脏代谢大学：会议回顾与报告摘要
Rev Cardiovasc Med. 2018 Mar 30;19(1):27-31. doi: 10.31083/j.rcm.2018.01.898.
6
Diabetes drugs ride a bumpy road.糖尿病药物的发展之路崎岖坎坷。
Nature. 2013 Dec 12;504(7479):198. doi: 10.1038/504198a.
7
Blood pressure control and components of the metabolic syndrome: the GOOD survey.血压控制与代谢综合征的组成部分：GOOD调查
Cardiovasc Diabetol. 2009 Sep 15;8:51. doi: 10.1186/1475-2840-8-51.
8
Age- and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the SardiNIA Study.奠基人群中心血管危险因素及亚临床血管病变的年龄和性别特异性知晓、治疗与控制：撒丁岛研究（SardiNIA研究）
Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):532-41. doi: 10.1016/j.numecd.2008.11.004. Epub 2009 Mar 25.
9
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.2型糖尿病和动脉粥样硬化性心血管疾病患者的代谢综合征：EMPA-REG OUTCOME试验的事后分析
Cardiovasc Diabetol. 2020 Nov 26;19(1):200. doi: 10.1186/s12933-020-01174-6.
10
Cardiologists' approach to managing cardiovascular risk in patients with type 2 diabetes.
J Diabetes. 2019 Jul;11(7):605-609. doi: 10.1111/1753-0407.12918. Epub 2019 May 1.

引用本文的文献

1
The future of cardiovascular and metabolic medical practice: evidence-based winds of change.心血管与代谢医学实践的未来：循证变革之风
Cardiovasc Endocrinol Metab. 2020 Jul 16;9(3):64-65. doi: 10.1097/XCE.0000000000000226. eCollection 2020 Sep.

本文引用的文献

1
GLP-1 receptor agonists and cardiovascular outcome trials: An update.GLP-1 受体激动剂与心血管结局试验：更新。
Hellenic J Cardiol. 2019 Nov-Dec;60(6):347-351. doi: 10.1016/j.hjc.2018.11.008. Epub 2018 Dec 6.
2
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.SGLT2 抑制剂用于 2 型糖尿病的心血管和肾脏结局的一级和二级预防：心血管结局试验的系统评价和荟萃分析。
Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.
3
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.达格列净与 2 型糖尿病患者的心血管结局
N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.
4
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.钠-葡萄糖共转运蛋白 2 抑制剂在糖尿病中的心脏和肾脏作用：美国心脏病学会最新综述
J Am Coll Cardiol. 2018 Oct 9;72(15):1845-1855. doi: 10.1016/j.jacc.2018.06.040. Epub 2018 Jul 31.
5
SGLT2 Inhibitors and Mechanisms of Hypertension.SGLT2 抑制剂与高血压的发生机制。
Curr Cardiol Rep. 2018 Jan 19;20(1):1. doi: 10.1007/s11886-018-0943-5.
6
8. Pharmacologic Approaches to Glycemic Treatment: .8. 血糖治疗的药物治疗方法： 。
Diabetes Care. 2018 Jan;41(Suppl 1):S73-S85. doi: 10.2337/dc18-S008.
7
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na/H exchanger, lowering of cytosolic Na and vasodilation.SGLT2 抑制剂在小鼠心肌细胞和心脏中的类效应：抑制 Na/H 交换器，降低细胞溶质 Na 并扩张血管。
Diabetologia. 2018 Mar;61(3):722-726. doi: 10.1007/s00125-017-4509-7. Epub 2017 Dec 2.
8
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults.全球 1975 年至 2016 年的体重指数、消瘦、超重和肥胖趋势：12890 万儿童、青少年和成年人 2416 项基于人群的测量研究的汇总分析。
Lancet. 2017 Dec 16;390(10113):2627-2642. doi: 10.1016/S0140-6736(17)32129-3. Epub 2017 Oct 10.
9
Effects of Oral and Non-Insulin Injectable Antidiabetic Treatment in Hypertension: A Systematic Review.口服和非胰岛素注射类抗糖尿病药物治疗对高血压的影响：一项系统评价。
Curr Pharm Des. 2017;23(25):3743-3750. doi: 10.2174/1381612823666170519144841.
10
Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe.超重、肥胖与心血管代谢多重疾病风险：对来自美国和欧洲16项队列研究的120813名成年人个体水平数据的汇总分析。
Lancet Public Health. 2017 May 19;2(6):e277-e285. doi: 10.1016/S2468-2667(17)30074-9. eCollection 2017 Jun.

Cardiologist as a cardiometabolic specialist.

作者信息

Katsi Vasiliki, Andrikou Ioannis, Tsioufis Costas, Tousoulis Dimitris

机构信息

Cardiology Department, Hippokration Hospital, Athens, Greece.

First Cardiology Clinic, Medical School, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

J Clin Hypertens (Greenwich). 2019 Sep;21(9):1432-1435. doi: 10.1111/jch.13636. Epub 2019 Jul 29.

DOI:10.1111/jch.13636
PMID:31355513
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8030368/
Abstract
摘要